• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5078805)   Today's Articles (1583)
For: Lee S, Kim BK, Kim SU, Park SY, Kim JK, Lee HW, Park JY, Kim DY, Ahn SH, Tak WY, Kweon YO, Lee JI, Lee KS, Kim HJ, Han KH. Clinical outcomes and prognostic factors of patients with advanced hepatocellular carcinoma treated with sorafenib as first-line therapy: a Korean multicenter study. J Gastroenterol Hepatol 2014;29:1463-1469. [PMID: 25273508 DOI: 10.1111/jgh.12542] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 01/22/2014] [Indexed: 12/12/2022]
Number Cited by Other Article(s)
1
Li H, Kong J, Si W, Wang T, Ji M, Li G, Liu J. Laparoscopic versus open liver resection for intrahepatic cholangiocarcinoma: Stratified analysis based on tumor burden score. Biosci Trends 2025;18:584-598. [PMID: 39662953 DOI: 10.5582/bst.2024.01277] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2024]
2
Öcal O, Schütte K, Zech CJ, Loewe C, van Delden O, Vandecaveye V, Verslype C, Gebauer B, Sengel C, Bargellini I, Iezzi R, Philipp A, Berg T, Klümpen HJ, Benckert J, Pech M, Gasbarrini A, Amthauer H, Bartenstein P, Sangro B, Malfertheiner P, Ricke J, Seidensticker M. Addition of Y-90 radioembolization increases tumor response and local disease control in hepatocellular carcinoma patients receiving sorafenib. Eur J Nucl Med Mol Imaging 2022;49:4716-4726. [PMID: 35916920 PMCID: PMC9606085 DOI: 10.1007/s00259-022-05920-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/23/2022] [Accepted: 07/16/2022] [Indexed: 11/30/2022]
3
Wang HW, Chuang PH, Su WP, Kao JT, Hsu WF, Lin CC, Huang GT, Lin JT, Lai HC, Peng CY. On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3758. [PMID: 34359658 PMCID: PMC8345148 DOI: 10.3390/cancers13153758] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2021] [Revised: 07/21/2021] [Accepted: 07/22/2021] [Indexed: 02/08/2023]  Open
4
Zhou TY, Tao GF, Chen SQ, Wang HL, Zhang YL, Zhou GH, Nie CH, Zhu TY, Wang BQ, Yu ZN, Jing L, Chen F, Sun JH. Complete Response of Hepatocellular Carcinoma with Macroscopic Vascular Invasion and Pulmonary Metastasis to the Combination of Drug-Eluting Beads Transarterial Chemoembolization and Huaier Granule: A Case Report. Onco Targets Ther 2021;14:3873-3880. [PMID: 34188493 PMCID: PMC8236259 DOI: 10.2147/ott.s309660] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/09/2021] [Accepted: 06/05/2021] [Indexed: 12/17/2022]  Open
5
Kim DS, Park SY, Kim BK, Park JY, Kim DY, Han KH, Lee YR, Tak WY, Kweon YO, Jung I, Han M, Kim EH, Ahn SH, Kim SU. Revised Korean Antiviral Guideline Reduces the Hepatitis B-related Hepatocellular Carcinoma Risk in Cirrhotic Patients. J Korean Med Sci 2021;36:e105. [PMID: 33904261 PMCID: PMC8076846 DOI: 10.3346/jkms.2021.36.e105] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/20/2020] [Accepted: 02/24/2021] [Indexed: 12/01/2022]  Open
6
Sorafenib for the treatment of hepatocellular carcinoma: a single-centre real-world study. Radiol Oncol 2020;54:233-236. [PMID: 32463391 PMCID: PMC7276638 DOI: 10.2478/raon-2020-0027] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2019] [Accepted: 12/01/2019] [Indexed: 12/21/2022]  Open
7
Berhane S, Fox R, García-Fiñana M, Cucchetti A, Johnson P. Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment. Br J Cancer 2019;121:117-124. [PMID: 31182766 PMCID: PMC6738086 DOI: 10.1038/s41416-019-0488-4] [Citation(s) in RCA: 23] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2019] [Revised: 05/01/2019] [Accepted: 05/10/2019] [Indexed: 12/13/2022]  Open
8
Hatanaka T, Kakizaki S, Uehara D, Nagashima T, Ueno T, Namikawa M, Saito S, Hosonuma K, Suzuki H, Naganuma A, Takagi H, Sato K, Uraoka T. Impact of the Prognostic Nutritional Index on the Survival of Japanese Patients with Hepatocellular Carcinoma Treated with Sorafenib: A Multicenter Retrospective Study. Intern Med 2019;58:1835-1844. [PMID: 30918170 PMCID: PMC6663544 DOI: 10.2169/internalmedicine.1594-18] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/25/2018] [Accepted: 01/07/2019] [Indexed: 12/21/2022]  Open
9
Wu M, Gao S, Song H, Zhang Z, Zheng Z, Yan Z, Wang X, Wang J, Liu L. Percutaneous microwave ablation combined with simultaneous transarterial chemoembolization for hepatocellular carcinoma with macrovascular invasion or extrahepatic metastases. J Interv Med 2019;2:55-59. [PMID: 34805873 PMCID: PMC8562208 DOI: 10.1016/j.jimed.2019.07.003] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]  Open
10
Park Y, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Yeon JE, Byun KS, Kim HS, Kim JH, Kim SU. Feasibility of dynamic risk assessment for patients with repeated trans-arterial chemoembolization for hepatocellular carcinoma. BMC Cancer 2019;19:363. [PMID: 30991968 PMCID: PMC6469056 DOI: 10.1186/s12885-019-5495-6] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2018] [Accepted: 03/20/2019] [Indexed: 12/21/2022]  Open
11
Díaz-González Á, Sanduzzi-Zamparelli M, Sapena V, Torres F, LLarch N, Iserte G, Forner A, da Fonseca L, Ríos J, Bruix J, Reig M. Systematic review with meta-analysis: the critical role of dermatological events in patients with hepatocellular carcinoma treated with sorafenib. Aliment Pharmacol Ther 2019;49:482-491. [PMID: 30695819 DOI: 10.1111/apt.15088] [Citation(s) in RCA: 37] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/10/2018] [Revised: 09/26/2018] [Accepted: 11/19/2018] [Indexed: 12/15/2022]
12
Mukthinuthalapati VVPK, Wang Y, Abu Omar Y, Syed M, Attar B. Single institution experience of sorafenib for advanced HCC in a US tertiary care hospital. J Gastrointest Oncol 2018;9:833-839. [PMID: 30505582 DOI: 10.21037/jgo.2018.06.09] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]  Open
13
Jeon MY, Lee HW, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Baek SE, Kim HS, Kim SU, Park MS. Reproducibility of European Association for the Study of the Liver criteria and modified Response Evaluation Criteria in Solid Tumors in patients treated with sorafenib. Liver Int 2018;38:1655-1663. [PMID: 29495116 DOI: 10.1111/liv.13731] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/05/2017] [Accepted: 02/17/2018] [Indexed: 02/13/2023]
14
Sánchez AIP, Roces LV, García IZ, López EL, Hernandez MAC, Parejo MIB, Peña-Díaz J. Value of α-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma. Oncol Lett 2018;15:8863-8870. [PMID: 29805623 DOI: 10.3892/ol.2018.8400] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2017] [Accepted: 02/23/2018] [Indexed: 12/31/2022]  Open
15
Bruix J, Cheng AL, Meinhardt G, Nakajima K, De Sanctis Y, Llovet J. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies. J Hepatol 2017;67:999-1008. [PMID: 28687477 DOI: 10.1016/j.jhep.2017.06.026] [Citation(s) in RCA: 448] [Impact Index Per Article: 56.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/19/2016] [Revised: 05/05/2017] [Accepted: 06/20/2017] [Indexed: 12/14/2022]
16
Cho IR, Lee HW, Song KJ, Kim BK, Kim SU, Kim DY, Ahn SH, Seong J, Han KH, Park JY. Conditional survival estimate in patients with Barcelona Clinic Liver Cancer stage B/C hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy with/without concurrent radiotherapy. Oncotarget 2017;8:79914-79926. [PMID: 29108373 PMCID: PMC5668106 DOI: 10.18632/oncotarget.20321] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/12/2017] [Accepted: 08/04/2017] [Indexed: 12/14/2022]  Open
17
Conroy G, Salleron J, Belle A, Bensenane M, Nani A, Ayav A, Peiffert D, Lopez A, Baumann C, Barraud H, Bronowicki JP. The prognostic value of inflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib. Oncotarget 2017;8:95853-95864. [PMID: 29221172 PMCID: PMC5707066 DOI: 10.18632/oncotarget.21401] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2017] [Accepted: 07/25/2017] [Indexed: 12/18/2022]  Open
18
Lee HW, Kim HS, Kim SU, Kim DY, Kim BK, Park JY, Ahn SH, Jeon MY, Heo JY, Park SY, Lee YR, Jang SK, Lee SH, Jang SY, Tak WY, Han KH. Survival Estimates after Stopping Sorafenib in Patients with Hepatocellular Carcinoma: NEXT Score Development and Validation. Gut Liver 2017;11:693-701. [PMID: 28651299 PMCID: PMC5593332 DOI: 10.5009/gnl16391] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/05/2016] [Revised: 11/28/2016] [Accepted: 01/10/2017] [Indexed: 12/16/2022]  Open
19
Zhang K, Yu J, Yu X, Han Z, Cheng Z, Liu F, Liang P. Clinical and survival outcomes of percutaneous microwave ablation for intrahepatic cholangiocarcinoma. Int J Hyperthermia 2017;34:292-297. [PMID: 28540822 DOI: 10.1080/02656736.2017.1327678] [Citation(s) in RCA: 36] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]  Open
20
Abdel-Rahman O, Lamarca A. Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival. Expert Rev Gastroenterol Hepatol 2017;11:75-83. [PMID: 27882800 DOI: 10.1080/17474124.2017.1264874] [Citation(s) in RCA: 46] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
21
von Felden J, Schulze K, Gil-Ibanez I, Werner T, Wege H. First- and Second-Line Targeted Systemic Therapy in Hepatocellular Carcinoma-An Update on Patient Selection and Response Evaluation. Diagnostics (Basel) 2016;6:E44. [PMID: 27916795 PMCID: PMC5192519 DOI: 10.3390/diagnostics6040044] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Revised: 11/22/2016] [Accepted: 11/23/2016] [Indexed: 12/30/2022]  Open
22
Subclassification of patients with intermediate-stage (Barcelona Clinic Liver Cancer stage-B) hepatocellular carcinoma using the up-to-seven criteria and serum tumor markers. Hepatol Int 2016;11:105-114. [PMID: 27766479 DOI: 10.1007/s12072-016-9771-0] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/28/2016] [Accepted: 10/03/2016] [Indexed: 12/13/2022]
23
Doyle A, Marsh P, Gill R, Rodov M, Mohsen W, Varma P, Hong T, Strasser SI, Bell S, Ryan M, Nicoll A, Lubel J, Gow PJ, Fink MA, Roberts S, Kemp W, Kronborg I, Arachchi N, Knight V, Dev A. Sorafenib in the treatment of hepatocellular carcinoma: a multi-centre real-world study. Scand J Gastroenterol 2016;51:979-85. [PMID: 27161568 DOI: 10.3109/00365521.2016.1166518] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
24
Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma. PLoS One 2015;10:e0138776. [PMID: 26421430 PMCID: PMC4589320 DOI: 10.1371/journal.pone.0138776] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2015] [Accepted: 09/03/2015] [Indexed: 02/06/2023]  Open
25
Shao YY, Hsu CH, Cheng AL. Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there? World J Gastroenterol 2015;21:10336-10347. [PMID: 26420960 PMCID: PMC4579880 DOI: 10.3748/wjg.v21.i36.10336] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/24/2015] [Revised: 05/26/2015] [Accepted: 08/31/2015] [Indexed: 02/06/2023]  Open
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA